Search - tctmd.com

Displaying 61 - 80 of 96

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

Shelley Wood

April 02, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

Advertisement

TCTMD’s Top 10 Most Popular Stories for March 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Evolocumab Not Cost-Effective at Current List Price

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content